Cogstate Ltd

Gain a direct line to Cogstate Ltd leadership

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Subscribe to receive announcements and updates from Cogstate.

Updates

Shareholder Information

Share Price

Shareholders

Financial Calendar

Investor Presentations

Announcements

Financial Reports

Investor Insight Series

Shareholder Day

Board of Directors

Corporate Governance

Company

Home

Why Invest

Inter

Cogstate Investor Hub

Cogstate FY2026 Financial Results

Watch the Podcast Now

upload.jpg

Recently, Cogstate CEO Brad O'Connor sat down with the Medidata CEO Anthony Costello as a guest on their “Dreamers to Disruptors” podcast. The delightful discussion includes commentary on Cogstate’s origins, our entry into the clinical trials space, and our ever-evolving offerings that leverage technology to reduce error. Brad and Anthony also talk about Cogstate’s leading role in Alzheimer’s disease (including supporting the Lilly Donanemab program), the impact of blood-based biomarkers, the future of CNS research, and a whole lot more.

Alzheimer’s Treatments, Dementia Early Detection, and the Future of CNS Research: Brad O’Connor